HuMax-CD20: Phase I/II start

GEN will start this summer an open-label, dose-escalation, U.S. Phase I/II study in 32 patients. Patients will receive 100, 300 or 500 mg of HuMax-CD20 followed by 3 weekly doses of 500, 1,000 or 2,00...